Data | Ora | Fonte | Titolo | Simbolo | Compagnia |
25/09/2024 | 23:15 | Edgar (US Regulatory) | Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] | NASDAQ:GRFS | Grifols SA |
23/09/2024 | 12:32 | IH Market News | Apollo Eyes $5 Billion Investment in Intel; TSMC and Samsung Explore UAE Chip Projects, and More | NASDAQ:GRFS | Grifols SA |
22/08/2024 | 11:37 | IH Market News | Schwab and Snowflake Retreat in Premarket, WeRide Postpones IPO, Halliburton Cyberattack, McDonald’s Instagram Hack | NASDAQ:GRFS | Grifols SA |
31/07/2024 | 14:00 | GlobeNewswire Inc. | GigaGen Receives FDA Clearance of IND Application for Phase 1 Trial of Recombinant Polyclonal for HBV Treatment, GIGA-2339 | NASDAQ:GRFS | Grifols SA |
29/07/2024 | 14:00 | GlobeNewswire Inc. | Grifols receives expanded XEMBIFY® (immune globulin subcutaneous human-klhw) label in U.S., strengthening its Ig portfolio for patients | NASDAQ:GRFS | Grifols SA |
03/07/2024 | 12:59 | IH Market News | Apple Joins OpenAI Board, Logitech President Opts Out of Reelection, and More News | NASDAQ:GRFS | Grifols SA |
01/07/2024 | 12:00 | GlobeNewswire Inc. | Grifols’ Biotest to achieve USD 1 billion in US sales of Yimmugo® over next seven years | NASDAQ:GRFS | Grifols SA |
18/06/2024 | 13:30 | GlobeNewswire Inc. | Grifols completes sale of a 20% equity stake in SRAAS and forges strategic alliance with Haier Group | NASDAQ:GRFS | Grifols SA |
17/06/2024 | 10:20 | GlobeNewswire Inc. | Grifols’ Biotest receives FDA approval for innovative Yimmugo® immunoglobulin to treat primary immunodeficiencies | NASDAQ:GRFS | Grifols SA |
19/04/2024 | 22:42 | PR Newswire (US) | Grifols 2023 Annual Report on Form 20-F filed with the SEC | NASDAQ:GRFS | Grifols SA |
18/04/2024 | 15:30 | GlobeNewswire Inc. | Grifols Celebrates 50 Years of Manufacturing Life-Changing Plasma-Derived Medicines for Patients at Flagship Site in Clayton, N.C. | NASDAQ:GRFS | Grifols SA |
15/04/2024 | 13:06 | IH Market News | Samsung Surpasses Apple in Q1 Smartphone Market; Salesforce in Talks to Acquire Informatica, and More News | NASDAQ:GRFS | Grifols SA |
04/04/2024 | 10:00 | GlobeNewswire Inc. | Grifols Procleix ArboPlex Assay® Receives CE Mark, the First and Only 4-in-1 NAT for Arbovirus Screening | NASDAQ:GRFS | Grifols SA |
22/03/2024 | 14:07 | IH Market News | FedEx Soars 13% with Profits Above Forecasts, Nike Hit by China Slowdown, and Latest News | NASDAQ:GRFS | Grifols SA |
08/03/2024 | 12:19 | IH Market News | CNOOC Oil Field Discovery in South China Sea, Grifols Surges 18% After KPMG Approval, and Latest News | NASDAQ:GRFS | Grifols SA |
14/02/2024 | 09:16 | GlobeNewswire Inc. | Grifols announces positive topline phase 3 fibrinogen clinical trial results | NASDAQ:GRFS | Grifols SA |
12/01/2024 | 12:10 | IH Market News | Wall Street Highlights: DocuSign Acquisition Battle, Tesla Berlin Production Halt, and More | NASDAQ:GRFS | Grifols SA |
10/01/2024 | 12:21 | IH Market News | Wall Street Highlights: Tesla Launches Restyled Model 3, VinFast Unveils Pickup Prototype, and More | NASDAQ:GRFS | Grifols SA |
29/12/2023 | 15:59 | Dow Jones News | Grifols Shares Rise on $1.76 Billion Sale of 20% Stake in Shanghai RAAS to Pay Down Debt | NASDAQ:GRFS | Grifols SA |
16/11/2023 | 11:00 | PR Newswire (US) | Grifols launches new solution to facilitate pre-transfusion compatibility testing in multiple myeloma patients | NASDAQ:GRFS | Grifols SA |
15/11/2023 | 14:00 | GlobeNewswire Inc. | Grifols Completes Cohort 1 in Clinical Study of Alpha-1 15%, Evaluating First-in-Human Subcutaneous Dosing Option for Patients with Alpha1-Antitrypsin Deficiency | NASDAQ:GRFS | Grifols SA |
06/11/2023 | 14:00 | GlobeNewswire Inc. | GigaGen Presents IND-Enabling Data and Phase 1 Trial Strategy for its Novel Anti-CTLA-4 Oncology Drug Candidate, GIGA-564, at SITC 2023 | NASDAQ:GRFS | Grifols SA |
25/10/2023 | 00:30 | GlobeNewswire Inc. | Araclon Biotech Presents Positive Final Results from Phase 2 Clinical Study of ABvac40 Alzheimer’s Vaccine at CTAD | NASDAQ:GRFS | Grifols SA |
19/10/2023 | 14:00 | GlobeNewswire Inc. | GigaGen Granted Expansion of Contract with US Department of Defense to Develop Synthetic Human Antibody Treatments for Botulinum Neurotoxins | NASDAQ:GRFS | Grifols SA |
28/09/2023 | 14:00 | GlobeNewswire Inc. | GigaGen Partners with the National Cancer Institute to Advance Oncology Drug Candidate GIGA-564 | NASDAQ:GRFS | Grifols SA |
01/08/2023 | 14:00 | GlobeNewswire Inc. | Grifols Accelerates Healthcare Innovation with Google Cloud’s AI and Analytics | NASDAQ:GRFS | Grifols SA |
20/07/2023 | 14:15 | GlobeNewswire Inc. | Grifols Achieves Positive Topline Results From Phase 4 Study of XEMBIFY® (immune globulin subcutaneous human-klhw) Evaluating Biweekly Dosing Option for Patients | NASDAQ:GRFS | Grifols SA |
18/07/2023 | 14:00 | GlobeNewswire Inc. | Grifols Completes Enrollment in Phase 3 Study of Long-term Albutein® (albumin-human injection) Therapy for Patients with Decompensated Cirrhosis | NASDAQ:GRFS | Grifols SA |
13/07/2023 | 14:00 | GlobeNewswire Inc. | Grifols Meets Enrollment Target in Phase 3 Study of Two Dose Regimens of Prolastin®-C in Patients with Emphysema Due to Alpha-1-Antitrypsin Deficiency | NASDAQ:GRFS | Grifols SA |
20/06/2023 | 13:13 | Edgar (US Regulatory) | Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) | NASDAQ:GRFS | Grifols SA |